Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | AURKA | O14965 | 8/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215364 | 0.91 | BRAF (0.85) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL13948741 | 0.84 | BRAF (1.00) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL14160585 | 0.82 | AURKA (0.79) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL4220074 | 0.82 | BRAF (0.75) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL4212767 | 0.79 | BRAF (0.71) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL1846987 | 0.79 | BRAF (0.71) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL17525364 | 0.78 | BRAF (0.80) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL19570224 | 0.78 | BRAF (0.82) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL12685023 | 0.78 | BRAF (0.69) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| SCHEMBL12684807 | 0.77 | BRAF (0.68) | BRAFCYP2D6CYP2C9AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018156-A1 | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-15 | — | — | US | claimed |
| US-20090018156-A1 | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-15 | — | — | US | disclosed |
| US-20090018156-A1 | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-15 | — | — | US | disclosed |
| US-20090018156-A1 | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-15 | — | — | US | disclosed |
| WO-2007090141-A2 | PYRROLO [2, 3, B] PYRIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018156-A1 | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885CYP2D6 2776/4885CYP2C9 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.